Skip to main content
Clinical Trials/NCT06241586
NCT06241586
Completed
Not Applicable

A Novel Surgical Strategy to Reduce Major Complications in Patients With Necrotizing Pancreatitis: A Retrospective Cohort Study

Tianjin Nankai Hospital1 site in 1 country271 target enrollmentJanuary 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute Pancreatitis
Sponsor
Tianjin Nankai Hospital
Enrollment
271
Locations
1
Primary Endpoint
major complications
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The goal of this observational study is to compare patient outcomes between the groups of patients admitted before and after the full implementation of the novel surgical strategy in patients with necrotizing pancreatitis. The main question it aims to answer are:

• the efficacy and safety of the novel surgical strategy To assess the efficacy and safety of the novel surgical strategy, all included patients were divided into two groups according to the timing of receiving treatment: 1) the early period group: patients admitted before January 2021 received the hybrid strategy of traditional and novel surgical strategies; and 2) the late period group: patients admitted during and after January 2021 received the complete novel surgical strategy.

Registry
clinicaltrials.gov
Start Date
January 1, 2019
End Date
October 1, 2022
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yang Yang

Resident physicians

Tianjin Nankai Hospital

Eligibility Criteria

Inclusion Criteria

  • Consecutive patients older than 18 years with necrotizing pancreatitis were included.

Exclusion Criteria

  • Patients who met one or more of the following criteria were excluded: (1) had a past medical history of acute pancreatitis; (2) had drainage or surgery for pancreatic necrosis in other hospitals before admission to our institute; and (3) did not complete the treatment strategy owing to nonmedical reasons.

Outcomes

Primary Outcomes

major complications

Time Frame: 90-day follow up

Secondary Outcomes

  • Admission of ICU(up to 90-days)
  • mortality(90-day follow up)
  • individual major complications(90-day follow up)
  • Length of hospital stay(up to 90-days)

Study Sites (1)

Loading locations...

Similar Trials